ProTrials will direct the Huntington’s trial across the US, Canada and Europe. Moreover, the company will also manage prostate cancer trial in the US and Canada.
Jodi Andrews, CEO, ProTrials, said: “Medivation’s repeated selection of ProTrials as a clinical trials partner is a nod to our track record of efficiency, cost effectiveness and most importantly, our GCP compliance in conducting clinical trials.”
“with prostate cancer being one of the most prevalent types of cancer in men, and Huntington’s disease having no treatments currently approved by the US Food and Drug Administration, these Phase III clinical trials are crucial for moving potentially life-saving treatments to market, he added.